Table 1 Input variables used in the probabilistic cost-effectiveness analysis of IPTi-SP^a on anaemia

IPTi-SP ^a total provider costs in US$ 2007 for the ITT population

Fixed costs to administer 3 doses IPTi-SP^a to a hypothetical target of 594 infants + variable costs to administer 1 dose IPTi-SP^a to an actual target of 97 infants, 2 doses to 92 infants and 3 doses to 315 infants

Triangular (97.70, 130.26, 162.82)

[24, 33]

±25%

IPTi-SP ^a total provider costs US$ 2007 for the ATP population

Fixed costs to administer 3 doses IPTi-SP^a to a hypothetical target of 594 infants + variable costs to administer 3 doses IPTi-SP^a to an actual target of 315 infants

Triangular (88.78, 118.38, 147.98)

[24, 33]

±25%

Protective Efficacy 18 months

Protective efficacy of IPTp-SP^a to avert anaemia at 18 months follow up (ITT analysis)

Triangular (-0.01,0.22,0.4)

[21]

[21]

Malaria incidence

Rate per person-years at risk in placebo group

Triangular (0.08,0.16,0.24)

[21]

±50%

Protective Efficacy 18 months

Protective efficacy of IPTp-SP^a to avert anaemia at 18 months follow up (ATP analysis)

Triangular (0.02, 0.27, 0.46)

[21]

[21]

Malaria incidence

Rate per person-years at risk in placebo group

Triangular (0.075, 0.15, 0.3)

[21]

±50%